TOL 2 / Bonsai Biotherapeutics - LARVOL DELTA

A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis. (PubMed, Front Immunol) - "We hypothesized that an efficacious drug candidate for antigen-specific therapy in MG should comprise a broad range of these auto-epitopes and be administered in a noninflammatory and tolerogenic context...Further, we did not observe any signs of toxicity or intolerability in animals treated with α1-ECD We conclude that intravenous treatment with α1-ECD is safe and effective in suppressing EAMG. α1-ECD is in preclinical development as a promising new drug candidate for MG."

Journal • CNS Disorders • Immunology • Myasthenia Gravis

Toleranzia AB starts industrial manufacturing of TOL2 [Google Translation] (Toleranzia Press Release) - "Toleranzia AB...hereby announces that the company has entered into an agreement with the Spanish contract manufacturer 3P Biopharmaceuticlas (3P) for the manufacture of the drug candidate TOL2 with the new optimized manufacturing method. The agreement aims at 3P producing TOL2 for the remaining preclinical studies and the substance of GMP quality for the forthcoming clinical study."

Commercial • Licensing / partnership